High Growth Tech Stocks In The United States To Watch

In This Article:

Over the last 7 days, the United States market has remained flat, yet it is up 21% over the past year with earnings forecasted to grow by 14% annually. In this context of steady growth and optimistic forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and solid financial health.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

29.07%

27.57%

★★★★★★

AsiaFIN Holdings

51.75%

82.69%

★★★★★★

Alkami Technology

21.99%

102.65%

★★★★★★

AVITA Medical

27.78%

55.33%

★★★★★★

TG Therapeutics

29.48%

45.20%

★★★★★★

Bitdeer Technologies Group

51.86%

122.49%

★★★★★★

Clene

61.16%

59.11%

★★★★★★

Alnylam Pharmaceuticals

21.83%

59.08%

★★★★★★

Lumentum Holdings

21.25%

118.58%

★★★★★★

Travere Therapeutics

30.33%

61.73%

★★★★★★

Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Apellis Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases, with a market cap of approximately $3.53 billion.

Operations: Apellis focuses on developing and commercializing proprietary therapeutics, generating $715.22 million in revenue from these activities. The company's strategy centers on inhibiting the complement system to address autoimmune and inflammatory diseases.

Apellis Pharmaceuticals, a biotechnology firm focusing on rare diseases, recently announced significant regulatory progress in Europe and Australia that underscores its potential within the high-growth tech sector of biotech. The European Medicines Agency’s validation of Aspaveli® for rare kidney diseases and the Australian approval of SYFOVRE® for a severe eye condition highlight Apellis's innovative approach to unmet medical needs. These developments are pivotal as Apellis transitions from R&D to commercial stages, evidenced by a robust 61.32% forecasted annual earnings growth and an R&D investment trend that aligns with its strategic focus on novel therapies. This trajectory sets Apellis apart in a competitive industry where innovation directly correlates with market success.